Does Ozempic work on the brain or the stomach? Both, but not equally. GLP-1 drugs slow the stomach at first, and that brake fades within weeks of steady use. The appetite effect does not fade: semaglutide reaches appetite circuits in the brain, and that is where the lasting weight loss comes from.
The argument of this piece is that the most repeated explanation of these drugs, that they keep food sitting in your stomach so you feel full, describes the side effects better than it describes the weight loss. The stomach effect is real, strongest early, and measurably weaker after a few weeks. The appetite effect is what the trials keep finding at 12 and 20 weeks, alongside fewer cravings and smaller meals, and the animal work traces it to the hypothalamus and brainstem. That distinction matters for anyone trying to understand why the weight returns when the drug stops, and why surgeons still worry about full stomachs. The brain explanation has its own weak spot, which the counterargument section takes seriously.
Nothing below is medical advice, and this page does not tell anyone whether to start, stop or continue any medicine. Doses appear only as the names of trial arms, the way the papers report them. Every figure comes from a source read on 19 November 2026 and linked at the foot of the page. A note on names: Ozempic is approved by the FDA for type 2 diabetes, and the same molecule, semaglutide, is approved for chronic weight management as Wegovy. Several studies below used older relatives in the same class, liraglutide and exenatide, and each is named where it appears. In everyday speech "Ozempic" covers the whole class, which is why this page uses the word people actually type.
Does Ozempic slow down your stomach?
GLP-1 drugs do slow the stomach, and the effect is strongest at the start. A 2017 trial at the Mayo Clinic by Halawi and colleagues, published in Lancet Gastroenterology and Hepatology, randomised 40 adults with obesity to liraglutide 3.0 mg or placebo and measured gastric emptying of a radiolabelled meal. At week 5 the median delay in emptying half of the solid meal was 70 minutes on liraglutide, against 4 minutes on placebo. By week 16 the delay had fallen to a median of 30.5 minutes. Nausea, the most common side effect, affected 12 of 19 people on the drug and 4 of 21 on placebo. Slower emptying is the part of the mechanism people can feel, which is one reason it dominates the popular explanation.
The same Mayo trial found the size of the early delay predicted later weight loss: the slower the emptying at week 5, the more weight lost by week 16, with a correlation coefficient of 0.567. That finding supports the stomach story, and the authors suggested measuring emptying as a marker of who responds. But the trial also shows the brake weakening by more than half over 11 weeks, in a drug taken daily. The obvious question is what happens over longer treatment, with the newer weekly drug, at the dose used for weight management. That has been measured too, and the answer moves the explanation away from the stomach.
Why does the stomach effect wear off?
The stomach effect wears off because the body stops responding to the same GLP-1 signal, a process called tachyphylaxis. The cleanest demonstration is a 2011 study in Diabetes by Nauck and colleagues, who infused natural GLP-1 into 9 healthy volunteers for 8.5 hours and gave them two liquid meals four hours apart. Emptying slowed significantly less after the second meal than after the first. A marker of vagal nerve activity fell after the first meal but not the second, which led the authors to place the fading at the level of the vagus nerve. Their conclusion was that the GLP-1 brake on the stomach is subject to rapid tachyphylaxis, and that its benefit for blood sugar after meals weakens with chronic use.
Friedrichsen and colleagues tested the long-acting case in 2021 in Diabetes, Obesity and Metabolism, with 72 adults with obesity on semaglutide 2.4 mg or placebo for 20 weeks. Gastric emptying was measured indirectly by how fast paracetamol taken with breakfast reached the blood. Over five hours, absorption was 8% higher on semaglutide, a difference that lost significance once body weight was taken into account, and there was no effect in the first hour, when a stomach delay would show most. The authors reported no evidence of delayed gastric emptying at week 20. All five authors were Novo Nordisk employees or paid contractors, and the paracetamol method is cruder than scintigraphy, but the direction matches the earlier work.
The stomach brake wears off within weeks. The appetite effect does not. That asymmetry is the whole answer.
How does Ozempic reduce appetite in the brain?
Semaglutide reduces appetite by acting on GLP-1 receptors in parts of the brain that regulate hunger and meal size, even though it does not cross the blood-brain barrier in the usual way. A 2020 study in JCI Insight by Gabery and colleagues, mostly Novo Nordisk scientists, tracked labelled semaglutide in rodents. The drug reached the brainstem, the septal nucleus and the hypothalamus through the circumventricular organs, small regions where the barrier is naturally leaky, and through select sites next to the brain ventricles. It switched on activity in 10 brain areas, including the lateral parabrachial nucleus, which controls when a meal ends, and it cut food intake without lowering energy expenditure.
An earlier study led by Novo Nordisk scientists in the Journal of Clinical Investigation in 2014, by Secher and colleagues, pinned down where the related drug liraglutide acts. In rats, weight loss did not depend on GLP-1 receptors in the vagus nerve, the area postrema or the paraventricular nucleus. Instead, labelled liraglutide was taken up by neurons in the arcuate nucleus of the hypothalamus that produce POMC and CART, which suppress appetite, while it indirectly damped the neurons that drive hunger. That is the hypothalamic story underneath the popular one about full stomachs: the drug acts on the circuits that decide how hungry a body feels, and it gets there through gaps that already exist in the barrier. Food noise sits on the same circuitry, which we cover in our piece on food noise.
Is there human evidence that GLP-1 drugs act on the brain?
The human evidence is indirect but consistent. Van Bloemendaal and colleagues, in Diabetes in 2014, scanned 48 people with functional MRI while they looked at food pictures. Intravenous exenatide, an older GLP-1 drug, reduced food intake and lowered food-cue responses in the insula, amygdala, putamen and orbitofrontal cortex, areas tied to appetite and reward. When the GLP-1 receptor was blocked first with exendin 9-39, those effects were largely blocked too, which points to the receptor rather than to nausea or a full stomach. This was a single session, not long-term treatment, so the finding shows that the brain responds to the signal rather than how much of the weight loss runs through that response.
| Study | Who and how long | Stomach finding | Appetite or brain finding |
|---|---|---|---|
| Nauck et al. (Diabetes, 2011) | 9 healthy volunteers, natural GLP-1 infused for 8.5 hours, two meals | Emptying slowed significantly less at the second meal than the first | Not measured |
| Halawi et al. (Lancet Gastroenterol Hepatol, 2017) | 40 adults with obesity, liraglutide 3.0 mg vs placebo, 16 weeks | Median delay 70 min at week 5, 30.5 min at week 16 | Lower maximum tolerated meal volume (750 vs 1,126 mL, p=0.054) |
| Blundell et al. (Diabetes Obes Metab, 2017) | 30 adults with obesity, semaglutide 1.0 mg vs placebo, 12 weeks, crossover | Not measured | Total daily energy intake 24% lower; fewer cravings |
| Friedrichsen et al. (Diabetes Obes Metab, 2021) | 72 adults with obesity, semaglutide 2.4 mg vs placebo, 20 weeks | No clear delay (paracetamol method) | Lunch energy intake 35% lower; fewer cravings |
| van Bloemendaal et al. (Diabetes, 2014) | 48 adults, intravenous exenatide, single session with fMRI | Not measured | Lower food-cue response in insula, amygdala, putamen, orbitofrontal cortex |
Sources: abstracts on PubMed, read on 19 November 2026. Different drugs, doses and designs: the rows show a pattern, not comparable effect sizes.
The appetite trials fill in the behaviour. In a 12-week crossover trial published in 2017 by Blundell and colleagues, semaglutide 1.0 mg cut total energy intake across all free meals in a day by 24% in 30 adults with obesity. Nausea ratings were similar to placebo, which argues against nausea as the explanation. People reported less hunger, fewer cravings, better control of eating and a lower preference for high-fat foods, and resting metabolic rate adjusted for lean mass did not change. In the 2021 trial with the 2.4 mg dose, energy intake at a free lunch was 35% lower on semaglutide, 1,736 against 2,676 kJ, at a point where the stomach showed no clear delay.
What is the case for the stomach after all?
The strongest case for the stomach is that the brake does not vanish completely, and that it matters clinically. In the Halawi trial the delay was smaller at week 16 but still significant against placebo, and the early delay predicted who lost the most weight. Most of the direct brain-access evidence comes from rodents and from studies run by the company that makes semaglutide. And the stomach is where real risks sit: a 2024 review in Lancet Gastroenterology and Hepatology by Jalleh, Camilleri, Horowitz and colleagues notes that marked slowing can leave food in the stomach and raise the risk of aspiration during surgery or endoscopy, and that pre-procedure guidance is hampered by a poor evidence base on long-acting GLP-1 drugs.
The stomach evidence does not rescue the full-stomach story as the explanation for weight loss. The stomach effect is largest in the first weeks, when weight loss is smallest, and the appetite effect persists at 20 weeks, when the stomach effect has largely gone. The withdrawal data point the same way. In the STEP 1 extension, published in 2022, people who stopped semaglutide regained two-thirds of their lost weight within a year, the pattern expected when a brain signal switches off. The fairer summary is that the stomach is part of the early response and part of the side-effect and surgery story, while the brain carries the lasting weight effect.
What does this change about how to read GLP-1 drugs?
Reading GLP-1 drugs as appetite drugs rather than stomach drugs explains three things the full-stomach story cannot. It explains why nausea often fades while the drugs keep working, why cravings and food preference change and not just meal size, and why the weight returns when treatment ends. It also explains why the newer drugs in development target more receptors in the same appetite and metabolic system rather than slowing the stomach harder, a point we follow in our pieces on the GIP receptor and on alcohol craving. Our regulatory tracker follows which of these drugs are approved and what changes next, and the newsletter sends each update with its source.
Sources
- Friedrichsen M et al., The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity, Diabetes Obes Metab 2021;23:754-762. pubmed.ncbi.nlm.nih.gov
- Blundell J et al., Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity, Diabetes Obes Metab 2017;19:1242-1251. pubmed.ncbi.nlm.nih.gov
- Nauck MA et al., Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans, Diabetes 2011;60:1561-1565. pubmed.ncbi.nlm.nih.gov
- Halawi H et al., Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial, Lancet Gastroenterol Hepatol 2017;2:890-899. pubmed.ncbi.nlm.nih.gov
- Gabery S et al., Semaglutide lowers body weight in rodents via distributed neural pathways, JCI Insight 2020;5:e133429. pubmed.ncbi.nlm.nih.gov
- Secher A et al., The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss, J Clin Invest 2014;124:4473-4488. pubmed.ncbi.nlm.nih.gov
- van Bloemendaal L et al., GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans, Diabetes 2014;63:4186-4196. pubmed.ncbi.nlm.nih.gov
- Jalleh RJ et al., Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions, Lancet Gastroenterol Hepatol 2024;9:957-964. pubmed.ncbi.nlm.nih.gov
- Wilding JPH et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes Obes Metab 2022;24:1553-1564. pubmed.ncbi.nlm.nih.gov
